marketcaparena
Search

    VCYT

    VERACYTE, INC.

    Company overview

    Market capitalization
    $3.64B
    Employees
    755
    Latest publication
    2026-09-29
    About VERACYTE, INC.

    Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ2 20122012-06-30 · USD
    Total Revenue139,071,000USD140,636,000USD131,872,000USD114,473,000USD118,632,000USD115,860,000USD114,428,000USD2,479,000USD
    Cost Of Revenue38,491,000USD35,956,000USD40,590,000USD34,965,000USD39,878,000USD36,850,000USD36,515,000USD2,651,000USD
    Gross Profit100,580,000USD104,680,000USD91,282,000USD79,508,000USD78,754,000USD79,010,000USD77,913,000USD0USD
    Research Development27,098,000USD20,849,000USD15,981,000USD17,720,000USD19,290,000USD17,574,000USD16,465,000USD1,677,000USD
    Selling General Administrative23,680,000USD1,417,000USD43,228,000USD52,342,000USD47,128,000USD40,451,000USD46,970,000USD5,359,000USD
    Unclassified Operating Expenses25,956,000USD13,557,000USD1,649,000USD——2,170,000USD2,737,000USD-7,036,000USD
    Total Operating Expenses76,734,000USD78,740,000USD68,336,000USD76,604,000USD74,579,000USD66,993,000USD73,307,000USD0USD
    Operating Income23,846,000USD25,940,000USD22,946,000USD2,904,000USD4,175,000USD12,017,000USD4,606,000USD0USD
    Interest Income3,478,000USD3,543,000USD3,482,000USD2,762,000USD2,861,000USD2,898,000USD2,699,000USD—
    Interest Expense0USD0USD0USD0USD0USD1,000USD1,000USD0USD
    Net Interest Income3,478,000USD3,543,000USD3,482,000USD2,762,000USD2,861,000USD2,897,000USD2,698,000USD—
    Income Before Tax29,974,000USD40,634,000USD18,889,000USD7,428,000USD3,443,000USD16,848,000USD7,361,000USD0USD
    Income Tax Expense1,267,000USD-515,000USD-248,000USD381,000USD-1,670,000USD1,693,000USD1,627,000USD0USD
    Tax Provision1,267,000USD-515,000USD-248,000USD381,000USD-1,670,000USD1,693,000USD1,627,000USD—
    Net Income28,707,000USD41,149,000USD19,137,000USD7,047,000USD5,113,000USD15,155,000USD5,734,000USD0USD
    Net Income From Continuing Ops28,707,000USD41,149,000USD19,137,000USD7,047,000USD5,113,000USD15,155,000USD5,734,000USD0USD
    Ebit29,974,000USD40,634,000USD18,889,000USD1,164,000USD3,443,000USD16,849,000USD7,362,000USD0USD
    Ebitda35,404,000USD45,932,000USD24,155,000USD6,526,000USD9,696,000USD22,727,000USD13,100,000USD—
    Depreciation And Amortization5,430,000USD5,298,000USD5,266,000USD5,362,000USD6,253,000USD5,878,000USD5,738,000USD—
    Reconciled Depreciation5,430,000USD5,298,000USD5,266,000USD5,362,000USD6,253,000USD5,878,000USD5,738,000USD—
    Total Other Income Expense Net6,128,000USD14,694,000USD-4,057,000USD4,524,000USD-732,000USD4,831,000USD2,755,000USD0USD
    Selling And Marketing Expenses—42,917,000USD7,478,000USD6,819,000USD7,679,000USD6,798,000USD7,135,000USD—
    Minority Interest———————0USD
    Discontinued Operations———————0USD
    Net Income Applicable To Common Shares———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USD
    Total Revenue517,145,000USD445,764,000USD
    Cost Of Revenue157,100,000USD147,619,000USD
    Gross Profit360,045,000USD298,145,000USD
    Research Development70,814,000USD69,294,000USD
    Selling General Administrative110,784,000USD178,272,000USD
    Selling And Marketing Expenses100,165,000USD27,772,000USD
    Unclassified Operating Expenses4,132,000USD6,665,000USD
    Total Operating Expenses285,895,000USD282,003,000USD
    Operating Income74,150,000USD16,142,000USD
    Interest Income12,724,000USD11,154,000USD
    Interest Expense1,000USD2,000USD
    Net Interest Income12,723,000USD11,152,000USD
    Income Before Tax68,201,000USD25,744,000USD
    Income Tax Expense1,848,000USD1,606,000USD
    Tax Provision1,848,000USD1,606,000USD
    Net Income66,353,000USD24,138,000USD
    Net Income From Continuing Ops66,353,000USD24,138,000USD
    Ebit68,201,000USD25,746,000USD
    Ebitda89,616,000USD49,205,000USD
    Depreciation And Amortization21,415,000USD23,459,000USD
    Reconciled Depreciation21,415,000USD23,459,000USD
    Total Other Income Expense Net-5,949,000USD9,602,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Assets1,436,400,000USD1,406,019,000USD1,367,787,000USD1,344,104,000USD1,315,411,000USD1,300,035,000USD1,275,021,000USD1,234,327,000USD
    Intangible Assets85,863,000USD89,148,000USD92,477,000USD95,806,000USD99,094,000USD102,301,000USD108,873,000USD112,532,000USD
    Other Current Assets11,587,000USD10,281,000USD14,643,000USD18,128,000USD17,762,000USD14,551,000USD13,604,000USD15,629,000USD
    Total Liab91,994,000USD96,443,000USD110,120,000USD123,047,000USD120,475,000USD124,069,000USD98,979,000USD101,804,000USD
    Total Stockholder Equity1,344,406,000USD1,309,576,000USD1,257,667,000USD1,221,057,000USD1,194,936,000USD1,175,966,000USD1,176,042,000USD1,132,523,000USD
    Other Current Liab44,111,000USD50,133,000USD61,944,000USD57,122,000USD50,295,000USD60,826,000USD51,316,000USD50,875,000USD
    Common Stock80,000USD79,000USD79,000USD79,000USD78,000USD78,000USD77,000USD77,000USD
    Capital Stock80,000USD79,000USD79,000USD79,000USD78,000USD78,000USD77,000USD77,000USD
    Retained Earnings-348,923,000USD-377,630,000USD-418,779,000USD-437,916,000USD-436,936,000USD-443,983,000USD-449,096,000USD-464,251,000USD
    Good Will767,154,000USD767,154,000USD767,154,000USD773,255,000USD754,272,000USD745,800,000USD762,117,000USD752,107,000USD
    Cash263,136,000USD362,578,000USD315,573,000USD219,499,000USD186,120,000USD239,087,000USD274,079,000USD235,915,000USD
    Cash And Short Term Investments439,060,000USD412,889,000USD366,428,000USD320,719,000USD287,355,000USD289,441,000USD274,079,000USD235,915,000USD
    Total Current Assets522,175,000USD488,376,000USD449,224,000USD414,681,000USD383,152,000USD372,267,000USD356,854,000USD321,106,000USD
    Total Current Liabilities56,115,000USD59,937,000USD72,152,000USD76,433,000USD75,125,000USD78,633,000USD70,313,000USD72,339,000USD
    Current Deferred Revenue749,000USD1,160,000USD417,000USD1,450,000USD1,712,000USD1,673,000USD2,033,000USD2,195,000USD
    Net Debt-223,803,000USD-322,924,000USD-275,120,000USD-168,853,000USD-135,619,000USD-188,350,000USD-254,385,000USD-215,177,000USD
    Short Term Debt4,347,000USD4,051,000USD4,282,000USD6,414,000USD7,409,000USD7,500,000USD7,294,000USD7,185,000USD
    Short Long Term Debt Total39,333,000USD39,654,000USD40,453,000USD50,646,000USD50,501,000USD50,737,000USD19,694,000USD20,738,000USD
    Short Term Investments175,924,000USD50,311,000USD50,855,000USD101,220,000USD101,235,000USD50,354,000USD——
    Net Receivables50,112,000USD44,660,000USD47,826,000USD50,814,000USD53,781,000USD46,525,000USD48,807,000USD50,304,000USD
    Inventory21,416,000USD20,546,000USD20,327,000USD25,020,000USD24,254,000USD21,750,000USD20,364,000USD19,258,000USD
    Accounts Payable6,908,000USD4,593,000USD5,509,000USD11,447,000USD15,709,000USD8,634,000USD9,670,000USD12,084,000USD
    Property Plant Equipment Net58,517,000USD58,791,000USD56,201,000USD57,231,000USD70,153,000USD71,142,000USD38,225,000USD40,407,000USD
    Property Plant Equipment Gross58,517,000USD102,271,000USD56,201,000USD57,231,000USD70,153,000USD110,531,000USD38,225,000USD40,407,000USD
    Accumulated Other Comprehensive Income-8,221,000USD-8,212,000USD-8,220,000USD-11,959,000USD-28,641,000USD-36,090,000USD-21,282,000USD-30,610,000USD
    Common Stock Shares Outstanding81,313,588shares81,387,089shares79,691,703shares79,905,000shares80,056,024shares79,905,412shares78,465,000shares77,163,149shares
    Non Current Assets Total914,225,000USD917,643,000USD918,563,000USD929,423,000USD932,259,000USD927,768,000USD918,167,000USD913,221,000USD
    Non Current Liabilities Total35,879,000USD36,506,000USD37,968,000USD46,614,000USD45,350,000USD45,436,000USD28,666,000USD29,465,000USD
    Non Current Liabilities Other257,000USD257,000USD583,000USD1,081,000USD1,016,000USD972,000USD14,796,000USD14,429,000USD
    Non Currrent Assets Other2,691,000USD2,550,000USD1,094,000USD3,131,000USD8,740,000USD8,525,000USD8,952,000USD8,175,000USD
    Net Working Capital466,060,000USD428,439,000USD377,072,000USD338,248,000USD308,027,000USD293,634,000USD286,541,000USD248,767,000USD
    Unclassified Non Current Liabilities35,622,000USD36,249,000USD37,385,000USD45,533,000USD44,334,000USD44,464,000USD13,870,000USD15,036,000USD
    Unclassified Equity1,701,390,000USD1,695,260,000USD1,684,508,000USD1,670,774,000USD1,660,357,000USD1,655,883,000USD1,646,266,000USD1,627,230,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets1,406,019,000USD1,300,035,000USD1,114,906,000USD1,156,422,000USD1,187,825,000USD457,163,000USD275,212,000USD120,638,000USD
    Intangible Assets89,148,000USD102,301,000USD88,593,000USD174,866,000USD202,731,000USD59,924,000USD65,019,000USD12,000,000USD
    Other Current Assets10,281,000USD14,551,000USD12,661,000USD11,469,000USD13,255,000USD3,197,000USD2,235,000USD2,387,000USD
    Total Liab96,443,000USD124,069,000USD70,804,000USD81,222,000USD91,311,000USD35,931,000USD35,757,000USD40,883,000USD
    Total Stockholder Equity1,309,576,000USD1,175,966,000USD1,044,102,000USD1,075,200,000USD1,096,514,000USD421,232,000USD239,455,000USD79,755,000USD
    Other Current Liab50,133,000USD60,826,000USD41,185,000USD44,020,000USD42,388,000USD11,705,000USD13,734,000USD9,186,000USD
    Common Stock79,000USD78,000USD73,000USD72,000USD71,000USD58,000USD50,000USD41,000USD
    Capital Stock79,000USD78,000USD73,000USD72,000USD71,000USD58,000USD50,000USD41,000USD
    Retained Earnings-377,630,000USD-443,983,000USD-468,121,000USD-393,717,000USD-357,157,000USD-281,594,000USD-246,685,000USD-234,086,000USD
    Good Will767,154,000USD745,800,000USD702,984,000USD695,891,000USD707,904,000USD2,725,000USD2,725,000USD1,057,000USD
    Cash362,578,000USD239,087,000USD216,454,000USD154,247,000USD173,197,000USD349,364,000USD159,317,000USD77,995,000USD
    Cash And Short Term Investments412,889,000USD289,441,000USD216,454,000USD178,852,000USD177,161,000USD349,364,000USD159,317,000USD77,995,000USD
    Total Current Assets488,376,000USD372,267,000USD285,621,000USD248,636,000USD243,102,000USD375,679,000USD187,687,000USD96,952,000USD
    Total Current Liabilities59,937,000USD78,633,000USD61,241,000USD62,614,000USD64,151,000USD16,781,000USD17,469,000USD13,059,000USD
    Current Deferred Revenue1,160,000USD1,673,000USD2,008,000USD2,613,000USD4,646,000USD371,000USD——
    Net Debt-322,924,000USD-188,350,000USD-203,824,000USD-139,529,000USD-154,344,000USD-337,048,000USD-145,710,000USD-52,713,000USD
    Short Term Debt4,051,000USD7,500,000USD5,105,000USD4,070,000USD4,757,000USD1,589,000USD1,407,000USD1,357,000USD
    Short Long Term Debt Total39,654,000USD50,737,000USD12,630,000USD14,718,000USD18,853,000USD12,316,000USD13,607,000USD25,282,000USD
    Short Term Investments50,311,000USD50,354,000USD0USD24,605,000USD3,964,000USD———
    Net Receivables44,660,000USD46,525,000USD40,378,000USD44,021,000USD41,461,000USD18,461,000USD19,329,000USD13,168,000USD
    Inventory20,546,000USD21,750,000USD16,128,000USD14,294,000USD11,225,000USD4,657,000USD6,806,000USD3,402,000USD
    Accounts Payable4,593,000USD8,634,000USD12,943,000USD11,911,000USD12,360,000USD3,116,000USD2,328,000USD2,516,000USD
    Property Plant Equipment Net58,791,000USD71,142,000USD30,861,000USD30,862,000USD31,141,000USD16,833,000USD17,741,000USD8,940,000USD
    Property Plant Equipment Gross102,271,000USD110,531,000USD63,721,000USD30,862,000USD31,141,000USD8,990,000USD17,741,000USD8,940,000USD
    Accumulated Other Comprehensive Income-8,212,000USD-36,090,000USD-24,018,000USD-31,346,000USD-15,083,000USD—0USD-12,006,000USD
    Common Stock Shares Outstanding80,573,140shares78,163,217shares72,644,487shares71,549,204shares67,890,328shares53,239,231shares46,138,177shares37,020,246shares
    Non Current Assets Total917,643,000USD927,768,000USD829,285,000USD907,786,000USD944,723,000USD81,484,000USD87,525,000USD23,686,000USD
    Non Current Liabilities Total36,506,000USD45,436,000USD9,563,000USD18,608,000USD27,160,000USD19,150,000USD18,288,000USD27,824,000USD
    Non Current Liabilities Other257,000USD972,000USD1,304,000USD14,077,000USD7,129,000USD18,340,000USD17,594,000USD—
    Non Currrent Assets Other2,550,000USD8,525,000USD6,847,000USD6,167,000USD2,947,000USD2,002,000USD2,040,000USD1,689,000USD
    Net Working Capital428,439,000USD293,634,000USD224,380,000USD186,022,000USD178,951,000USD358,898,000USD170,218,000USD83,893,000USD
    Unclassified Non Current Liabilities36,249,000USD44,464,000USD8,259,000USD-7,560,000USD1,375,000USD-8,423,000USD-6,088,000USD-3,899,000USD
    Unclassified Equity1,695,260,000USD1,655,883,000USD1,536,095,000USD1,500,119,000USD1,468,612,000USD702,710,000USD486,040,000USD325,765,000USD
    Other Assets—-33,985,000USD1USD6,167,000USD2,947,000USD9,845,000USD2,040,000USD1,689,000USD
    Deferred Long Term Liab———4,531,000USD5,592,000USD——3,899,000USD
    Other Liab———7,560,000USD13,064,000USD8,423,000USD6,088,000USD3,899,000USD
    Net Tangible Assets———379,309,000USD185,879,000USD358,583,000USD171,711,000USD66,698,000USD
    Short Long Term Debt————1,127,000USD——1,357,000USD
    Unclassified Current Liabilities————-1,127,000USD——-1,357,000USD
    Long Term Debt—————810,000USD694,000USD23,925,000USD
    Unclassified Non Current Assets—————-9,845,000USD-2,040,000USD-1,689,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ1 20242024-03-31 · USD
    Net Income28,707,000USD19,137,000USD-980,000USD7,047,000USD5,113,000USD15,155,000USD5,734,000USD-1,864,000USD
    Depreciation5,430,000USD5,266,000USD5,489,000USD5,362,000USD6,253,000USD5,878,000USD5,738,000USD5,590,000USD
    Stock Based Compensation12,761,000USD10,757,000USD10,985,000USD10,958,000USD9,629,000USD8,747,000USD9,854,000USD8,019,000USD
    Other Non Cash Items54,000USD3,304,000USD16,826,000USD-2,635,000USD7,972,000USD287,000USD2,303,000USD2,240,000USD
    Change To Account Receivables-5,567,000USD425,000USD2,770,000USD-7,053,000USD1,991,000USD1,690,000USD-3,627,000USD-6,459,000USD
    Change To Inventory-870,000USD221,000USD-565,000USD-2,298,000USD-1,696,000USD-909,000USD-963,000USD-2,303,000USD
    Change In Working Capital-11,727,000USD6,380,000USD1,226,000USD-15,385,000USD-4,200,000USD-91,000USD5,803,000USD-22,831,000USD
    Total Cash From Operating Activities35,215,000USD44,757,000USD33,605,000USD5,362,000USD24,524,000USD29,963,000USD29,575,000USD-8,966,000USD
    Capital Expenditures-2,962,000USD-2,792,000USD-1,286,000USD-1,819,000USD-4,141,000USD-2,242,000USD-2,770,000USD-2,134,000USD
    Free Cash Flow32,253,000USD41,965,000USD32,319,000USD3,543,000USD20,383,000USD27,721,000USD26,805,000USD-11,100,000USD
    Investments-124,999,000USD48,263,000USD-224,000USD-51,818,000USD-54,141,000USD-2,242,000USD-2,770,000USD2,878,000USD
    Total Cashflows From Investing Activities-127,961,000USD48,263,000USD-224,000USD-51,818,000USD-54,141,000USD-2,242,000USD-2,770,000USD2,878,000USD
    Total Cash From Financing Activities-6,629,000USD2,977,000USD-566,000USD-6,484,000USD-4,510,000USD10,289,000USD-11,000USD-864,000USD
    Change In Cash-99,442,000USD96,074,000USD33,388,000USD-52,866,000USD-34,528,000USD38,156,000USD26,733,000USD-7,060,000USD
    Begin Period Cash Flow362,578,000USD219,499,000USD187,765,000USD240,631,000USD275,159,000USD237,003,000USD210,270,000USD217,330,000USD
    End Period Cash Flow263,136,000USD315,573,000USD221,153,000USD187,765,000USD240,631,000USD275,159,000USD237,003,000USD210,270,000USD
    Other Cashflows From Financing Activities-9,364,000USD-2,814,000USD-566,000USD-6,484,000USD-4,510,000USD10,289,000USD-11,000USD-864,000USD
    Unclassified Financing Cash Flow2,735,000USD5,791,000USD2,380,000USD9,451,000USD3,274,000USD2,180,000USD1,303,000USD3,832,000USD
    Unclassified Investing Cash Flow—2,792,000USD-49,775,000USD1,819,000USD4,141,000USD2,242,000USD2,770,000USD2,134,000USD
    Sale Purchase Of Stock——-2,380,000USD-9,451,000USD-3,274,000USD-2,180,000USD-1,303,000USD-3,832,000USD
    Other Cashflows From Investing Activities——51,061,000USD—————
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income66,353,000USD24,138,000USD-74,404,000USD-36,560,000USD-75,563,000USD-34,909,000USD-12,599,000USD-22,999,000USD
    Depreciation21,415,000USD23,459,000USD27,188,000USD25,928,000USD19,593,000USD7,944,000USD4,117,000USD3,920,000USD
    Stock Based Compensation43,601,000USD36,249,000USD33,141,000USD26,734,000USD22,519,000USD12,995,000USD9,807,000USD5,958,000USD
    Other Non Cash Items7,820,000USD12,802,000USD66,299,000USD7,681,000USD3,869,000USD4,740,000USD312,000USD251,000USD
    Change To Account Receivables-708,000USD-6,405,000USD3,887,000USD-4,495,000USD-8,571,000USD955,000USD-6,161,000USD-452,000USD
    Change To Inventory-2,861,000USD-5,871,000USD-1,694,000USD-3,011,000USD-1,464,000USD1,061,000USD-3,404,000USD1,922,000USD
    Change In Working Capital-2,301,000USD-21,319,000USD-4,163,000USD-16,381,000USD4,219,000USD-481,000USD-4,846,000USD-651,000USD
    Total Cash From Operating Activities136,307,000USD75,096,000USD44,222,000USD7,535,000USD-31,621,000USD-9,711,000USD-3,232,000USD-13,521,000USD
    Capital Expenditures-9,677,000USD-11,287,000USD-9,961,000USD-8,549,000USD-5,376,000USD-2,837,000USD-2,756,000USD-1,874,000USD
    Free Cash Flow126,630,000USD63,809,000USD34,261,000USD-1,014,000USD-36,997,000USD-12,548,000USD-5,988,000USD-15,395,000USD
    Investments3,313,000USD-56,275,000USD-8,825,000USD-20,838,000USD3,000,000USD-1,000,000USD-42,733,000USD-1,874,000USD
    Total Cashflows From Investing Activities-9,209,000USD-56,275,000USD15,112,000USD-29,387,000USD-739,206,000USD-3,837,000USD-42,733,000USD-1,874,000USD
    Total Cash From Financing Activities-4,222,000USD4,904,000USD2,837,000USD3,494,000USD596,320,000USD203,595,000USD127,287,000USD59,499,000USD
    Change In Cash123,595,000USD23,301,000USD62,334,000USD-18,950,000USD-176,021,000USD190,047,000USD81,322,000USD44,104,000USD
    Begin Period Cash Flow240,631,000USD217,330,000USD154,996,000USD173,946,000USD349,967,000USD159,920,000USD78,598,000USD34,494,000USD
    End Period Cash Flow364,226,000USD240,631,000USD217,330,000USD154,996,000USD173,946,000USD349,967,000USD159,920,000USD78,598,000USD
    Other Cashflows From Investing Activities-2,845,000USD——-20,838,000USD-162,419,000USD-1,000,000USD23,000USD—
    Other Cashflows From Financing Activities-18,304,000USD-15,089,000USD2,837,000USD4,775,000USD2,499,000USD9,864,000USD14,647,000USD4,753,000USD
    Unclassified Financing Cash Flow14,082,000USD19,993,000USD6,741,000USD6,334,000USD604,131,000USD201,521,000USD139,802,000USD55,068,000USD
    Net Borrowings—0USD0USD-1,281,000USD-1,281,000USD-100,000USD-25,208,000USD-292,000USD
    Unclassified Investing Cash Flow—11,287,000USD33,898,000USD20,838,000USD-574,411,000USD—2,733,000USD1,874,000USD
    Sale Purchase Of Stock——-6,741,000USD-3,167,000USD-9,029,000USD-3,845,000USD-977,000USD-30,000USD
    Issuance Of Capital Stock——0USD0USD593,821,000USD193,831,000USD137,848,000USD55,038,000USD
    Unclassified Operating Cash Flow——-3,839,000USD—-6,258,000USD———
    Change To Liabilities———152,000USD5,155,000USD711,000USD-141,000USD-1,568,000USD
    Dividends Paid———-3,167,000USD—-3,845,000USD-977,000USD—
    Cash And Cash Equivalents Changes———-18,358,000USD-174,507,000USD190,047,000USD81,322,000USD44,104,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductBiopharmaceutical And Other301,000USD0001384101-26-000031
    Q1 2026Quarterly · 2026-03-31ProductBiopharmaceutical And Other Biopharmaceutical Revenue301,000USD0001384101-26-000031
    Q1 2026Quarterly · 2026-03-31ProductBiopharmaceutical And Other Contract Manufacturing And Testing0USD0001384101-26-000031
    Q1 2026Quarterly · 2026-03-31ProductTesting135,091,000USD0001384101-26-000031
    Q1 2026Quarterly · 2026-03-31ProductTesting Other4,200,000USD0001384101-26-000031
    FY 2025Yearly · 2025-12-31GeographyInternational20,547,000USD0001384101-26-000010
    FY 2025Yearly · 2025-12-31GeographyUnited States496,598,000USD0001384101-26-000010
    FY 2025Yearly · 2025-12-31ProductBiopharmaceutical And Other9,664,000USD0001384101-26-000010
    FY 2025Yearly · 2025-12-31ProductBiopharmaceutical And Other Biopharmaceutical Revenue6,536,000USD0001384101-26-000010
    FY 2025Yearly · 2025-12-31ProductBiopharmaceutical And Other Contract Manufacturing And Testing3,128,000USD0001384101-26-000010
    FY 2025Yearly · 2025-12-31ProductTesting493,154,000USD0001384101-26-000010
    FY 2025Yearly · 2025-12-31ProductTesting Other6,200,000USD0001384101-26-000010
    Q3 2025Quarterly · 2025-09-30ProductBiopharmaceutical And Other1,801,000USD0001384101-25-000130
    Q3 2025Quarterly · 2025-09-30ProductBiopharmaceutical And Other Biopharmaceutical Revenue646,000USD0001384101-25-000130
    Q3 2025Quarterly · 2025-09-30ProductBiopharmaceutical And Other Contract Manufacturing And Testing169,000USD0001384101-25-000130
    Q3 2025Quarterly · 2025-09-30ProductTesting127,756,000USD0001384101-25-000130
    Q3 2025Quarterly · 2025-09-30ProductTesting Other1,500,000USD0001384101-25-000130
    Q1 2025Quarterly · 2025-03-31ProductBiopharmaceutical And Other Biopharmaceutical Revenue2,297,000USD0001384101-26-000031
    Q1 2025Quarterly · 2025-03-31ProductBiopharmaceutical And Other Contract Manufacturing And Testing1,287,000USD0001384101-26-000031
    Q1 2025Quarterly · 2025-03-31ProductProduct3,580,000USD0001384101-26-000031
    Q1 2025Quarterly · 2025-03-31ProductTesting107,309,000USD0001384101-26-000031
    Q1 2025Quarterly · 2025-03-31ProductTesting Other400,000USD0001384101-26-000031
    FY 2024Yearly · 2024-12-31GeographyInternational22,227,000USD0001384101-26-000010
    FY 2024Yearly · 2024-12-31GeographyUnited States423,537,000USD0001384101-26-000010
    FY 2023Yearly · 2023-12-31GeographyInternational26,526,000USD0001384101-26-000010
    FY 2023Yearly · 2023-12-31GeographyUnited States334,525,000USD0001384101-26-000010
    Q3 2023Quarterly · 2023-09-30ProductBiopharmaceutical And Other Biopharmaceutical Revenue2,833,000USD0001384101-24-000162
    Q3 2023Quarterly · 2023-09-30ProductBiopharmaceutical And Other Contract Manufacturing And Testing1,243,000USD0001384101-24-000162
    Q3 2023Quarterly · 2023-09-30ProductProduct4,020,000USD0001384101-24-000162
    Q3 2023Quarterly · 2023-09-30ProductTesting82,012,000USD0001384101-24-000162
    Q3 2023Quarterly · 2023-09-30ProductTesting Other900,000USD0001384101-24-000162
    Q2 2023Quarterly · 2023-06-30ProductBiopharmaceutical And Other Biopharmaceutical Revenue3,310,000USD0001384101-23-000142
    Q2 2023Quarterly · 2023-06-30ProductBiopharmaceutical And Other Contract Manufacturing And Testing1,252,000USD0001384101-23-000142
    Q2 2023Quarterly · 2023-06-30ProductProduct4,011,000USD0001384101-23-000142
    Q2 2023Quarterly · 2023-06-30ProductTesting81,749,000USD0001384101-23-000142
    Q1 2023Quarterly · 2023-03-31ProductBiopharmaceutical And Other Biopharmaceutical Revenue4,447,000USD0001384101-23-000067
    Q1 2023Quarterly · 2023-03-31ProductBiopharmaceutical And Other Contract Manufacturing And Testing1,687,000USD0001384101-23-000067
    Q1 2023Quarterly · 2023-03-31ProductProduct3,892,000USD0001384101-23-000067
    Q1 2023Quarterly · 2023-03-31ProductTesting72,396,000USD0001384101-23-000067
    Q4 2022Quarterly · 2022-12-31ProductBiopharmaceutical And Other Biopharmaceutical Revenue5,520,000USDLegacy provider
    Q4 2022Quarterly · 2022-12-31ProductBiopharmaceutical And Other Contract Manufacturing And Testing1,277,000USDLegacy provider
    Q4 2022Quarterly · 2022-12-31ProductProduct3,231,000USDLegacy provider
    Q4 2022Quarterly · 2022-12-31ProductTesting70,269,000USDLegacy provider
    FY 2022Yearly · 2022-12-31GeographyInternational33,613,000USD0001384101-25-000014
    FY 2022Yearly · 2022-12-31GeographyUnited States262,923,000USD0001384101-25-000014
    FY 2022Yearly · 2022-12-31ProductBiopharmaceutical And Other Biopharmaceutical Revenue26,341,000USD0001384101-23-000016
    FY 2022Yearly · 2022-12-31ProductBiopharmaceutical And Other Collaboration Milestones0USD0001384101-23-000016
    FY 2022Yearly · 2022-12-31ProductBiopharmaceutical And Other Contract Manufacturing And Testing7,019,000USD0001384101-23-000016
    FY 2022Yearly · 2022-12-31ProductProduct12,632,000USD0001384101-23-000016
    FY 2022Yearly · 2022-12-31ProductTesting250,544,000USD0001384101-23-000016
    Q3 2022Quarterly · 2022-09-30ProductBiopharmaceutical And Other Biopharmaceutical Revenue6,368,000USD0001384101-23-000163
    Q3 2022Quarterly · 2022-09-30ProductBiopharmaceutical And Other Contract Manufacturing And Testing1,333,000USD0001384101-23-000163
    Q3 2022Quarterly · 2022-09-30ProductProduct3,314,000USD0001384101-23-000163
    Q3 2022Quarterly · 2022-09-30ProductTesting64,577,000USD0001384101-23-000163
    FY 2021Yearly · 2021-12-31GeographyInternational18,532,000USD0001384101-24-000017
    FY 2021Yearly · 2021-12-31GeographyUnited States200,982,000USD0001384101-24-000017
    FY 2021Yearly · 2021-12-31ProductBiopharmaceutical And Other Collaboration Milestones4,000,000USD0001384101-22-000028
    FY 2021Yearly · 2021-12-31ProductBiopharmaceutical And Other Contract Manufacturing2,872,000USD0001384101-22-000028
    FY 2021Yearly · 2021-12-31ProductBiopharmaceutical And Other Contract Testing383,000USD0001384101-22-000028
    FY 2021Yearly · 2021-12-31ProductBiopharmaceutical And Other Development Rights0USD0001384101-22-000028
    FY 2021Yearly · 2021-12-31ProductBiopharmaceutical And Other Development Services10,387,000USD0001384101-22-000028
    FY 2021Yearly · 2021-12-31ProductBiopharmaceutical And Other Milestones Excluding Collaboration350,000USD0001384101-22-000028
    FY 2021Yearly · 2021-12-31ProductBiopharmaceutical And Other Provision Of Data1,876,000USD0001384101-22-000028
    FY 2021Yearly · 2021-12-31ProductProduct11,464,000USD0001384101-22-000028
    FY 2021Yearly · 2021-12-31ProductTesting188,182,000USD0001384101-22-000028
    FY 2020Yearly · 2020-12-31GeographyInternational7,869,000USD0001384101-23-000016
    FY 2020Yearly · 2020-12-31GeographyUnited States109,614,000USD0001384101-23-000016
    FY 2020Yearly · 2020-12-31ProductBiopharmaceutical And Other Collaboration Milestones0USD0001384101-22-000028
    FY 2020Yearly · 2020-12-31ProductBiopharmaceutical And Other Contract Manufacturing0USD0001384101-22-000028
    FY 2020Yearly · 2020-12-31ProductBiopharmaceutical And Other Contract Testing0USD0001384101-22-000028
    FY 2020Yearly · 2020-12-31ProductBiopharmaceutical And Other Development Services4,123,000USD0001384101-22-000028
    FY 2020Yearly · 2020-12-31ProductBiopharmaceutical And Other Provision Of Data1,545,000USD0001384101-22-000028
    FY 2020Yearly · 2020-12-31ProductProduct9,845,000USD0001384101-22-000028
    FY 2020Yearly · 2020-12-31ProductTesting101,970,000USD0001384101-22-000028
    FY 2019Yearly · 2019-12-31GeographyInternational1,215,000USD0001384101-22-000028
    FY 2019Yearly · 2019-12-31GeographyUnited States119,153,000USD0001384101-22-000028
    FY 2019Yearly · 2019-12-31ProductBiopharmaceutical And Other Collaboration Milestones4,000,000USD0001384101-22-000028
    FY 2019Yearly · 2019-12-31ProductBiopharmaceutical And Other Contract Manufacturing0USD0001384101-22-000028
    FY 2019Yearly · 2019-12-31ProductBiopharmaceutical And Other Contract Testing0USD0001384101-22-000028
    FY 2019Yearly · 2019-12-31ProductBiopharmaceutical And Other Development Rights0USD0001384101-22-000028
    FY 2019Yearly · 2019-12-31ProductBiopharmaceutical And Other Development Services1,000,000USD0001384101-22-000028
    FY 2019Yearly · 2019-12-31ProductBiopharmaceutical And Other Milestones Excluding Collaboration0USD0001384101-22-000028
    FY 2019Yearly · 2019-12-31ProductBiopharmaceutical And Other Provision Of Data7,090,000USD0001384101-22-000028
    FY 2019Yearly · 2019-12-31ProductProduct923,000USD0001384101-22-000028
    FY 2019Yearly · 2019-12-31ProductTesting107,355,000USD0001384101-22-000028
    FY 2018Yearly · 2018-12-31GeographyInternational235,000USD0001384101-21-000012
    FY 2018Yearly · 2018-12-31GeographyUnited States91,773,000USD0001384101-21-000012
    FY 2018Yearly · 2018-12-31ProductBiopharmaceutical950,000USD0001384101-21-000012
    FY 2018Yearly · 2018-12-31ProductCollaboration0USD0001384101-21-000012
    FY 2018Yearly · 2018-12-31ProductProduct0USD0001384101-21-000012
    FY 2018Yearly · 2018-12-31ProductTesting91,058,000USD0001384101-21-000012
    FY 2017Yearly · 2017-12-31ProductBiopharmaceutical0USD0001384101-20-000015
    FY 2017Yearly · 2017-12-31ProductCollaboration0USD0001384101-20-000015
    FY 2017Yearly · 2017-12-31ProductProduct0USD0001384101-20-000015
    FY 2017Yearly · 2017-12-31ProductTesting71,953,000USD0001384101-20-000015

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.